At the 20th Congress of the European Hematology Association (EHA), Giuseppe Saglio, MD, of the University of Turin, Turin, Italy, discusses the latest clinical trial results of tyrosine kinase inhibitors (TKIs) for the treatment of patients with chronic myeloid leukemia. As therapeutic strategies with TKIs continue to improve patient outcomes, the importance of monitoring and optimally managing patients is emphasized.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates